Recro Pharma, Inc. (REPH) financial statements (2022 and earlier)

Company profile

Business Address 1 E. UWCHLAN AVE, SUITE 112
EXTON, PA 19341
State of Incorp. PA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25,21723,49045,72411,55823,76021,48722,787
Cash and cash equivalents25,21723,49045,72411,55823,76021,48722,787
Receivables11,91313,74612,81312,4289,03313,63411,584
Inventory, net of allowances, customer advances and progress billings8,9179,4407,8788,63611,61211,58011,772
Inventory8,9179,4407,8788,63611,61211,58011,772
Contract with customer, asset8,5657,3147,3506,9947,3309,7288,911
Other undisclosed current assets2,9172,1012,0282,3252,3342,4922,986
Total current assets:57,52956,09175,79341,94154,06958,92158,040
Noncurrent Assets
Operating lease, right-of-use asset5,9245,963449    
Property, plant and equipment51,70850,02141,86742,77043,84143,48042,448
Intangible assets, net (including goodwill)44,91045,5614,3194,3735,0195,6646,310
Goodwill41,07739,5684,3194,3194,3194,3194,319
Intangible assets, net (excluding goodwill)3,8335,993 547001,3451,991
Other undisclosed noncurrent assets2461462470486503399
Total noncurrent assets:102,788101,69146,63747,61349,34649,64749,157
TOTAL ASSETS:160,317157,782122,43089,554103,415108,568107,197
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,0859,7725,3035,5276,329657871
Accounts payable2,0851,9161,1551,5381,804657871
Accrued liabilities 7,8564,1483,9894,525  
Debt   2,5791,4749,4587,289
Due to related parties2,0392,039     
Other undisclosed current liabilities13,6111,049   4,8024,870
Total current liabilities:17,73512,8605,3038,1067,80314,91713,030
Noncurrent Liabilities
Long-term debt and lease obligation97,05995,97689,78088,899108,097108,399109,265
Long-term debt, excluding current maturities92,12791,02989,78088,899108,097108,399109,265
Operating lease, liability4,9324,947     
Liabilities, other than long-term debt3,3694,2746059261,248  
Deferred revenue 1,0156059261,248  
Due to related parties3,3693,259     
Other undisclosed noncurrent liabilities90188326347367385313
Total noncurrent liabilities:100,518100,43890,71190,172109,712108,784109,578
Total liabilities:118,253113,29896,01498,278117,515123,701122,608
Stockholders' equity
Stockholders' equity attributable to parent42,06444,48426,416(8,724)(14,100)(15,133)(15,411)
Common stock467466465310286236236
Additional paid in capital287,351287,415265,862232,111219,998207,345204,940
Accumulated deficit(245,754)(243,397)(239,911)(241,145)(234,384)(222,714)(220,587)
Total stockholders' equity:42,06444,48426,416(8,724)(14,100)(15,133)(15,411)
TOTAL LIABILITIES AND EQUITY:160,317157,782122,43089,554103,415108,568107,197

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues22,30318,23718,01716,8039,91319,28715,522
Cost of revenue
(Cost of Goods and Services Sold)
(15,706)(13,160)(12,334)(14,337)(12,505)(11,741)(11,634)
Gross profit:6,5975,0775,6832,466(2,592)7,5463,888
Operating expenses(5,500)(4,741)(3,841)(5,329)(4,646)(5,064)(4,905)
Operating income (loss):1,0973361,842(2,863)(7,238)2,482(1,017)
Interest and debt expense(3,454)(3,822)(608)(3,898)(4,432)(4,609)(4,995)
Income (loss) from continuing operations before income taxes:(2,357)(3,486)1,234(6,761)(11,670)(2,127)(6,012)
Other undisclosed income from continuing operations677   7,135  
Income (loss) from continuing operations:(1,680)(3,486)1,234(6,761)(4,535)(2,127)(6,012)
Loss from discontinued operations      (7,596)
Income (loss) before gain (loss) on sale of properties:(1,680)(3,486)1,234(6,761)(4,535)(2,127)(13,608)
Other undisclosed net loss(677)   (7,135)  
Net income (loss):(2,357)(3,486)1,234(6,761)(11,670)(2,127)(13,608)
Other undisclosed net income attributable to parent      7,596
Net income (loss) available to common stockholders, diluted:(2,357)(3,486)1,234(6,761)(11,670)(2,127)(6,012)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(2,357)(3,486)1,234(6,761)(11,670)(2,127)(13,608)
Comprehensive income (loss), net of tax, attributable to parent:(2,357)(3,486)1,234(6,761)(11,670)(2,127)(13,608)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: